-
1
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, E. Van Cutsem, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
-
(2004)
N. Engl. J. Med.
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
2
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J. L. Canon, J. L. Van Laethem, J. Maurel, G. Richardson, M. Wolf, R. G. Amado, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
Humblet, Y.4
Hendlisz, A.5
Neyns, B.6
Canon, J.L.7
Van Laethem, J.L.8
Maurel, J.9
Richardson, G.10
Wolf, M.11
Amado, R.G.12
-
3
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. D. Patterson, D. D. Chang, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
Juan, T.7
Sikorski, R.8
Suggs, S.9
Radinsky, R.10
Patterson, S.D.11
Chang, D.D.12
-
4
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, T. J. Price, L. Shepherd, H. J. Au, C. Langer, M. J. Moore, J. R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
O'Callaghan, C.J.4
Tu, D.5
Tebbutt, N.C.6
Simes, R.J.7
Chalchal, H.8
Shapiro, J.D.9
Robitaille, S.10
Price, T.J.11
Shepherd, L.12
Au, H.J.13
Langer, C.14
Moore, M.J.15
Zalcberg, J.R.16
-
5
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
J. Y. Douillard, K. S. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocákova, P. Ruff, M. Błasiñska-Morawiec, M. Šmakal, J. L. Canon, M. Rother, R. Williams, A. Rong, J. Wiezorek, R. Sidhu, S. D. Patterson, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
Tabernero, J.4
Burkes, R.5
Barugel, M.6
Humblet, Y.7
Bodoky, G.8
Cunningham, D.9
Jassem, J.10
Rivera, F.11
Kocákova, I.12
Ruff, P.13
Błasiñska-Morawiec, M.14
Šmakal, M.15
Canon, J.L.16
Rother, M.17
Williams, R.18
Rong, A.19
Wiezorek, J.20
Sidhu, R.21
Patterson, S.D.22
more..
-
6
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
Sartore-Bianchi, A.4
Arena, S.5
Saletti, P.6
De Dosso, S.7
Mazzucchelli, L.8
Frattini, M.9
Siena, S.10
Bardelli, A.11
-
7
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K. T. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, A. O. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
-
(2010)
Lancet Oncol.
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
Kalogeras, K.T.7
Kotoula, V.8
Papamichael, D.9
Laurent-Puig, P.10
Penault-Llorca, F.11
Rougier, P.12
Vincenzi, B.13
Santini, D.14
Tonini, G.15
Cappuzzo, F.16
Frattini, M.17
Molinari, F.18
Saletti, P.19
De Dosso, S.20
Martini, M.21
Bardelli, A.22
Siena, S.23
Sartore-Bianchi, A.24
Tabernero, J.25
Macarulla, T.26
Di Fiore, F.27
Gangloff, A.O.28
Ciardiello, F.29
Pfeiffer, P.30
Qvortrup, C.31
Hansen, T.P.32
Van Cutsem, E.33
Piessevaux, H.34
Lambrechts, D.35
Delorenzi, M.36
Tejpar, S.37
more..
-
8
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
-
W. De Roock, V. De Vriendt, N. Normanno, F. Ciardiello, S. Tejpar, KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12, 594-603 (2011).
-
(2011)
Lancet Oncol.
, vol.12
, pp. 594-603
-
-
De Roock, W.1
De Vriendt, V.2
Normanno, N.3
Ciardiello, F.4
Tejpar, S.5
-
9
-
-
84879240684
-
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
-
E. Valtorta, S. Misale, A. Sartore-Bianchi, I. D. Nagtegaal, F. Paraf, C. Lauricella, V. Dimartino, S. Hobor, B. Jacobs, C. Ercolani, S. Lamba, E. Scala, S. Veronese, P. Laurent-Puig, S. Siena, S. Tejpar, M. Mottolese, C. J. Punt, M. Gambacorta, A. Bardelli, F. Di Nicolantonio, KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int. J. Cancer 133, 1259-1265 (2013).
-
(2013)
Int. J. Cancer
, vol.133
, pp. 1259-1265
-
-
Valtorta, E.1
Misale, S.2
Sartore-Bianchi, A.3
Nagtegaal, I.D.4
Paraf, F.5
Lauricella, C.6
Dimartino, V.7
Hobor, S.8
Jacobs, B.9
Ercolani, C.10
Lamba, S.11
Scala, E.12
Veronese, S.13
Laurent-Puig, P.14
Siena, S.15
Tejpar, S.16
Mottolese, M.17
Punt, C.J.18
Gambacorta, M.19
Bardelli, A.20
Di Nicolantonio, F.21
more..
-
10
-
-
84862772839
-
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
-
A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti, C. Isella, D. Corà, F. Di Nicolantonio, M. Buscarino, C. Petti, D. Ribero, N. Russolillo, A. Muratore, P. Massucco, A. Pisacane, L. Molinaro, E. Valtorta, A. Sartore-Bianchi, M. Risio, L. Capussotti, M. Gambacorta, S. Siena, E. Medico, A. Sapino, S. Marsoni, P. M. Comoglio, A. Bardelli, L. Trusolino, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
-
(2011)
Cancer Discov.
, vol.1
, pp. 508-523
-
-
Bertotti, A.1
Migliardi, G.2
Galimi, F.3
Sassi, F.4
Torti, D.5
Isella, C.6
Corà, D.7
Di Nicolantonio, F.8
Buscarino, M.9
Petti, C.10
Ribero, D.11
Russolillo, N.12
Muratore, A.13
Massucco, P.14
Pisacane, A.15
Molinaro, L.16
Valtorta, E.17
Sartore-Bianchi, A.18
Risio, M.19
Capussotti, L.20
Gambacorta, M.21
Siena, S.22
Medico, E.23
Sapino, A.24
Marsoni, S.25
Comoglio, P.M.26
Bardelli, A.27
Trusolino, L.28
more..
-
11
-
-
80052591747
-
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
-
K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, D. Ercan, A. Rogers, M. Roncalli, M. Takeda, Y. Fujisaka, J. Philips, T. Shimizu, O. Maenishi, Y. Cho, J. Sun, A. Destro, K. Taira, K. Takeda, T. Okabe, J. Swanson, H. Itoh, M. Takada, E. Lifshits, K.Okuno, J. A. Engelman, R. A. Shivdasani, K. Nishio, M. Fukuoka, M. Varella-Garcia, K. Nakagawa, P. A. Jänne, Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
-
(2011)
Sci. Transl. Med.
, vol.3
, pp. 99ra86
-
-
Yonesaka, K.1
Zejnullahu, K.2
Okamoto, I.3
Satoh, T.4
Cappuzzo, F.5
Souglakos, J.6
Ercan, D.7
Rogers, A.8
Roncalli, M.9
Takeda, M.10
Fujisaka, Y.11
Philips, J.12
Shimizu, T.13
Maenishi, O.14
Cho, Y.15
Sun, J.16
Destro, A.17
Taira, K.18
Takeda, K.19
Okabe, T.20
Swanson, J.21
Itoh, H.22
Takada, M.23
Lifshits, E.24
Okuno, K.25
Engelman, J.A.26
Shivdasani, R.A.27
Nishio, K.28
Fukuoka, M.29
Varella-Garcia, M.30
Nakagawa, K.31
Jänne, P.A.32
more..
-
12
-
-
84875217382
-
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
-
V. Martin, L. Landi, F. Molinari, G. Fountzilas, R. Geva, A. Riva, P. Saletti, S. De Dosso, A. Spitale, S. Tejpar, K. T. Kalogeras, L. Mazzucchelli, M. Frattini, F. Cappuzzo, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br. J. Cancer 108, 668-675 (2013).
-
(2013)
Br. J. Cancer
, vol.108
, pp. 668-675
-
-
Martin, V.1
Landi, L.2
Molinari, F.3
Fountzilas, G.4
Geva, R.5
Riva, A.6
Saletti, P.7
De Dosso, S.8
Spitale, A.9
Tejpar, S.10
Kalogeras, K.T.11
Mazzucchelli, L.12
Frattini, M.13
Cappuzzo, F.14
-
13
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
A. Bardelli, S. Corso, A. Bertotti, S. Hobor, E. Valtorta, G. Siravegna, A. Sartore-Bianchi, E. Scala, A. Cassingena, D. Zecchin, M. Apicella, G. Migliardi, F. Galimi, C. Lauricella, C. Zanon, T. Perera, S. Veronese, G. Corti, A. Amatu, M. Gambacorta, L. A. Diaz Jr., M. Sausen, V. E. Velculescu, P. Comoglio, L. Trusolino, F. Di Nicolantonio, S. Giordano, S. Siena, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
-
(2013)
Cancer Discov.
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
Corso, S.2
Bertotti, A.3
Hobor, S.4
Valtorta, E.5
Siravegna, G.6
Sartore-Bianchi, A.7
Scala, E.8
Cassingena, A.9
Zecchin, D.10
Apicella, M.11
Migliardi, G.12
Galimi, F.13
Lauricella, C.14
Zanon, C.15
Perera, T.16
Veronese, S.17
Corti, G.18
Amatu, A.19
Gambacorta, M.20
Diaz, L.A.21
Sausen, M.22
Velculescu, V.E.23
Comoglio, P.24
Trusolino, L.25
Di Nicolantonio, F.26
Giordano, S.27
Siena, S.28
more..
-
14
-
-
84873819555
-
Which drug, and when, for patients with BRAF-mutant melanoma?
-
S. Jang, M. B. Atkins, Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 14, e60-e69 (2013).
-
(2013)
Lancet Oncol.
, vol.14
, pp. e60-e69
-
-
Jang, S.1
Atkins, M.B.2
-
15
-
-
84884549747
-
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
-
B. Hallberg, R. H. Palmer, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat. Rev. Cancer 13, 685-700 (2013).
-
(2013)
Nat. Rev. Cancer
, vol.13
, pp. 685-700
-
-
Hallberg, B.1
Palmer, R.H.2
-
16
-
-
17844362179
-
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
-
M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Di Nicolantonio, M. Gambacorta, S. Siena, A. Bardelli, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol. 6, 279-286 (2005).
-
(2005)
Lancet Oncol.
, vol.6
, pp. 279-286
-
-
Moroni, M.1
Veronese, S.2
Benvenuti, S.3
Marrapese, G.4
Sartore-Bianchi, A.5
Di Nicolantonio, F.6
Gambacorta, M.7
Siena, S.8
Bardelli, A.9
-
17
-
-
41549097718
-
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
-
F. Cappuzzo, G. Finocchiaro, E. Rossi, P. A. Jänne, C. Carnaghi, C. Calandri, K. Bencardino, C. Ligorio, F. Ciardiello, T. Pressiani, A. Destro, M. Roncalli, L. Crino, W. A. Franklin, A. Santoro, M. Varella-Garcia, EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19, 717-723 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, pp. 717-723
-
-
Cappuzzo, F.1
Finocchiaro, G.2
Rossi, E.3
Jänne, P.A.4
Carnaghi, C.5
Calandri, C.6
Bencardino, K.7
Ligorio, C.8
Ciardiello, F.9
Pressiani, T.10
Destro, A.11
Roncalli, M.12
Crino, L.13
Franklin, W.A.14
Santoro, A.15
Varella-Garcia, M.16
-
18
-
-
70049091759
-
Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
-
M. Scartozzi, I. Bearzi, A. Mandolesi, C. Pierantoni, F. Loupakis, A. Zaniboni, F. Negri, A. Quadri, F. Zorzi, E. Galizia, R. Berardi, T. Biscotti, R. Labianca, G. Masi, A. Falcone, S. Cascinu, Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 9, 303 (2009).
-
(2009)
BMC Cancer
, vol.9
, pp. 303
-
-
Scartozzi, M.1
Bearzi, I.2
Mandolesi, A.3
Pierantoni, C.4
Loupakis, F.5
Zaniboni, A.6
Negri, F.7
Quadri, A.8
Zorzi, F.9
Galizia, E.10
Berardi, R.11
Biscotti, T.12
Labianca, R.13
Masi, G.14
Falcone, A.15
Cascinu, S.16
-
19
-
-
73349094741
-
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
-
P. Laurent-Puig, A. Cayre, G. Manceau, E. Buc, J. B. Bachet, T. Lecomte, P. Rougier, A. Lievre, B. Landi, V. Boige, M. Ducreux, M. Ychou, F. Bibeau, O. Bouché, J. Reid, S. Stone, F. Penault-Llorca, Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27, 5924-5930 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5924-5930
-
-
Laurent-Puig, P.1
Cayre, A.2
Manceau, G.3
Buc, E.4
Bachet, J.B.5
Lecomte, T.6
Rougier, P.7
Lievre, A.8
Landi, B.9
Boige, V.10
Ducreux, M.11
Ychou, M.12
Bibeau, F.13
Bouché, O.14
Reid, J.15
Stone, S.16
Penault-Llorca, F.17
-
20
-
-
34548238762
-
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
-
S. Khambata-Ford, C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, X. Huang, C. H. Takimoto, A. K. Godwin, B. R. Tan, S. S. Krishnamurthi, H. A. Burris III, E. A. Poplin, M. Hidalgo, J. Baselga, E. A. Clark, D. J. Mauro, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 3230-3237
-
-
Khambata-Ford, S.1
Garrett, C.R.2
Meropol, N.J.3
Basik, M.4
Harbison, C.T.5
Wu, S.6
Wong, T.W.7
Huang, X.8
Takimoto, C.H.9
Godwin, A.K.10
Tan, B.R.11
Krishnamurthi, S.S.12
Burris, H.A.13
Poplin, E.A.14
Hidalgo, M.15
Baselga, J.16
Clark, E.A.17
Mauro, D.J.18
-
21
-
-
73349098041
-
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
-
B. Jacobs, W. De Roock, H. Piessevaux, R. Van Oirbeek, B. Biesmans, J. De Schutter, S. Fieuws, J. Vandesompele, M. Peeters, J. L. Van Laethem, Y. Humblet, F. Pénault-Llorca, G. De Hertogh, P. Laurent-Puig, E. Van Cutsem, S. Tejpar, Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 27, 5068-5074 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5068-5074
-
-
Jacobs, B.1
De Roock, W.2
Piessevaux, H.3
Van Oirbeek, R.4
Biesmans, B.5
De Schutter, J.6
Fieuws, S.7
Vandesompele, J.8
Peeters, M.9
Van Laethem, J.L.10
Humblet, Y.11
Pénault-Llorca, F.12
De Hertogh, G.13
Laurent-Puig, P.14
Van Cutsem, E.15
Tejpar, S.16
-
22
-
-
77949887855
-
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of a phase I dose-escalation study
-
J. Tabernero, A. Cervantes, F. Rivera, E. Martinelli, F. Rojo, A. von Heydebreck, T. Macarulla, E. Rodriguez-Braun, M. Eugenia Vega-Villegas, S. Senger, F. J. Ramos, S. Roselló, I. Celik, C. Stroh, J. Baselga, F. Ciardiello, Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of a phase I dose-escalation study. J. Clin. Oncol. 28, 1181-1189 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1181-1189
-
-
Tabernero, J.1
Cervantes, A.2
Rivera, F.3
Martinelli, E.4
Rojo, F.5
Von Heydebreck, A.6
Macarulla, T.7
Rodriguez-Braun, E.8
Eugenia Vega-Villegas, M.9
Senger, S.10
Ramos, F.J.11
Roselló, S.12
Celik, I.13
Stroh, C.14
Baselga, J.15
Ciardiello, F.16
-
23
-
-
84868034781
-
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation
-
L. Trusolino, A. Bertotti, Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation. Cancer Discov. 2, 876-880 (2012).
-
(2012)
Cancer Discov.
, vol.2
, pp. 876-880
-
-
Trusolino, L.1
Bertotti, A.2
-
24
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
25
-
-
84857640868
-
The insulin and insulin-like growth factor receptor family in neoplasia: An update
-
M. Pollak, The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat. Rev. Cancer 12, 159-169 (2012).
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 159-169
-
-
Pollak, M.1
-
26
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
W. De Roock, D. J. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena, S. Lamba, S. Arena, M. Frattini, H. Piessevaux, E. Van Cutsem, C. J. O'Callaghan, S. Khambata-Ford, J. R. Zalcberg, J. Simes, C. S. Karapetis, A. Bardelli, S. Tejpar, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820 (2010).
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
Sartore-Bianchi, A.4
Tu, D.5
Siena, S.6
Lamba, S.7
Arena, S.8
Frattini, M.9
Piessevaux, H.10
Van Cutsem, E.11
O'Callaghan, C.J.12
Khambata-Ford, S.13
Zalcberg, J.R.14
Simes, J.15
Karapetis, C.S.16
Bardelli, A.17
Tejpar, S.18
-
27
-
-
84871368013
-
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
-
S. Q. Ashraf, A. M. Nicholls, J. L. Wilding, T. G. Ntouroupi, N. J. Mortensen, W. F. Bodmer, Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc. Natl. Acad. Sci. U.S.A. 109, 21046-21051 (2012).
-
(2012)
Proc. Natl. Acad. Sci. U.S.A.
, vol.109
, pp. 21046-21051
-
-
Ashraf, S.Q.1
Nicholls, A.M.2
Wilding, J.L.3
Ntouroupi, T.G.4
Mortensen, N.J.5
Bodmer, W.F.6
-
28
-
-
84896078397
-
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
-
S.Misale, S. Arena, S. Lamba, G. Siravegna, A. Lallo, S. Hobor, M. Russo, M. Buscarino, L. Lazzari, A. Sartore-Bianchi, K. Bencardino, A. Amatu, C. Lauricella, E. Valtorta, S. Siena, F. Di Nicolantonio, A. Bardelli, Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra26 (2014).
-
(2014)
Sci. Transl. Med.
, vol.6
, pp. 224ra26
-
-
Misale, S.1
Arena, S.2
Lamba, S.3
Siravegna, G.4
Lallo, A.5
Hobor, S.6
Russo, M.7
Buscarino, M.8
Lazzari, L.9
Sartore-Bianchi, A.10
Bencardino, K.11
Amatu, A.12
Lauricella, C.13
Valtorta, E.14
Siena, S.15
Di Nicolantonio, F.16
Bardelli, A.17
-
29
-
-
73149120253
-
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
-
J. M. Carboni, M. Wittman, Z. Yang, F. Lee, A. Greer, W. Hurlburt, S. Hillerman, C. Cao, G. H. Cantor, J. Dell-John, C. Chen, L. Discenza, K. Menard, A. Li, G. Trainor, D. Vyas, R. Kramer, R. M. Attar, M. M. Gottardis, BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8, 3341-3349 (2009).
-
(2009)
Mol. Cancer Ther.
, vol.8
, pp. 3341-3349
-
-
Carboni, J.M.1
Wittman, M.2
Yang, Z.3
Lee, F.4
Greer, A.5
Hurlburt, W.6
Hillerman, S.7
Cao, C.8
Cantor, G.H.9
Dell-John, J.10
Chen, C.11
Discenza, L.12
Menard, K.13
Li, A.14
Trainor, G.15
Vyas, D.16
Kramer, R.17
Attar, R.M.18
Gottardis, M.M.19
-
30
-
-
84863239500
-
Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: Structural insights, chemical diversity and molecular evolution
-
M. Jin, J. Wang, E. Buck, M. J. Mulvihill, Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: Structural insights, chemical diversity and molecular evolution. Future Med. Chem. 4, 315-328 (2012).
-
(2012)
Future Med. Chem.
, vol.4
, pp. 315-328
-
-
Jin, M.1
Wang, J.2
Buck, E.3
Mulvihill, M.J.4
-
31
-
-
84875733362
-
Anticancer IGF1R classes take more knocks
-
M. Guha, Anticancer IGF1R classes take more knocks. Nat. Rev. Drug Discov. 12, 250 (2013).
-
(2013)
Nat. Rev. Drug Discov.
, vol.12
, pp. 250
-
-
Guha, M.1
-
32
-
-
84883179862
-
Targeting the ERBB family in cancer: Couples therapy
-
N. Tebbutt, M. W. Pedersen, T. G. Johns, Targeting the ERBB family in cancer: Couples therapy. Nat. Rev. Cancer 13, 663-673 (2013).
-
(2013)
Nat. Rev. Cancer
, vol.13
, pp. 663-673
-
-
Tebbutt, N.1
Pedersen, M.W.2
Johns, T.G.3
-
33
-
-
70349684791
-
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
-
L. Regales, Y. Gong, R. Shen, E. de Stanchina, I. Vivanco, A. Goel, J. A. Koutcher, M. Spassova, O. Ouerfelli, I. K. Mellinghoff, M. F. Zakowski, K. A. Politi, W. Pao, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000-3010 (2009).
-
(2009)
J. Clin. Invest.
, vol.119
, pp. 3000-3010
-
-
Regales, L.1
Gong, Y.2
Shen, R.3
De Stanchina, E.4
Vivanco, I.5
Goel, A.6
Koutcher, J.A.7
Spassova, M.8
Ouerfelli, O.9
Mellinghoff, I.K.10
Zakowski, M.F.11
Politi, K.A.12
Pao, W.13
-
34
-
-
84857236823
-
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial
-
J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T. W. Chang, Z. Horváth, M. Coccia-Portugal, J. Domont, L. M. Tseng, G. Kunz, J. H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R. D. Gelber, M. Piccart-Gebhart; NeoALTTO Study Team, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
-
(2012)
Lancet
, vol.379
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
Di Cosimo, S.4
De Azambuja, E.5
Aura, C.6
Gómez, H.7
Dinh, P.8
Fauria, K.9
Van Dooren, V.10
Aktan, G.11
Goldhirsch, A.12
Chang, T.W.13
Horváth, Z.14
Coccia-Portugal, M.15
Domont, J.16
Tseng, L.M.17
Kunz, G.18
Sohn, J.H.19
Semiglazov, V.20
Lerzo, G.21
Palacova, M.22
Probachai, V.23
Pusztai, L.24
Untch, M.25
Gelber, R.D.26
Piccart-Gebhart, M.27
more..
-
35
-
-
84864066561
-
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study
-
K. L. Blackwell, H. J. Burstein, A. M. Storniolo, H. S. Rugo, G. Sledge, G. Aktan, C. Ellis, A. Florance, S. Vukelja, J. Bischoff, J. Baselga, J. O'Shaughnessy, Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J. Clin. Oncol. 30, 2585-2592 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2585-2592
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
Rugo, H.S.4
Sledge, G.5
Aktan, G.6
Ellis, C.7
Florance, A.8
Vukelja, S.9
Bischoff, J.10
Baselga, J.11
O'Shaughnessy, J.12
-
36
-
-
84862987061
-
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
-
A. J. Weickhardt, T. J. Price, G. Chong, V. Gebski, N. Pavlakis, T. G. Johns, A. Azad, E. Skrinos, K. Fluck, A. Dobrovic, R. Salemi, A. M. Scott, J. M. Mariadason, N. C. Tebbutt, Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol. 30, 1505-1512 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 1505-1512
-
-
Weickhardt, A.J.1
Price, T.J.2
Chong, G.3
Gebski, V.4
Pavlakis, N.5
Johns, T.G.6
Azad, A.7
Skrinos, E.8
Fluck, K.9
Dobrovic, A.10
Salemi, R.11
Scott, A.M.12
Mariadason, J.M.13
Tebbutt, N.C.14
-
37
-
-
46749156706
-
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
-
M. Guix, A. C. Faber, S. E. Wang, M. G. Olivares, Y. Song, S. Qu, C. Rinehart, B. Seidel, D. Yee, C. L. Arteaga, J. A. Engelman, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609-2619 (2008).
-
(2008)
J. Clin. Invest.
, vol.118
, pp. 2609-2619
-
-
Guix, M.1
Faber, A.C.2
Wang, S.E.3
Olivares, M.G.4
Song, Y.5
Qu, S.6
Rinehart, C.7
Seidel, B.8
Yee, D.9
Arteaga, C.L.10
Engelman, J.A.11
-
38
-
-
77950809059
-
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
-
S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K. K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, J. Settleman, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
-
(2010)
Cell
, vol.141
, pp. 69-80
-
-
Sharma, S.V.1
Lee, D.Y.2
Li, B.3
Quinlan, M.P.4
Takahashi, F.5
Maheswaran, S.6
McDermott, U.7
Azizian, N.8
Zou, L.9
Fischbach, M.A.10
Wong, K.K.11
Brandstetter, K.12
Wittner, B.13
Ramaswamy, S.14
Classon, M.15
Settleman, J.16
-
39
-
-
77957962308
-
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
-
D. L. Reidy, E. Vakiani, M. G. Fakih, M. W. Saif, J. R. Hecht, N. Goodman-Davis, E. Hollywood, J. Shia, J. Schwartz, K. Chandrawansa, A. Dontabhaktuni, H. Youssoufian, D. B. Solit, L. B. Saltz, Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 28, 4240-4246 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 4240-4246
-
-
Reidy, D.L.1
Vakiani, E.2
Fakih, M.G.3
Saif, M.W.4
Hecht, J.R.5
Goodman-Davis, N.6
Hollywood, E.7
Shia, J.8
Schwartz, J.9
Chandrawansa, K.10
Dontabhaktuni, A.11
Youssoufian, H.12
Solit, D.B.13
Saltz, L.B.14
-
40
-
-
84905968151
-
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
-
E. Van Cutsem, C. Eng, E. Nowara, A. Swieboda-Sadlej, N. Tebbutt, E. P. Mitchell, I. Davidenko, J. Stephenson, M. E. Elez, H. Prenen, H. Deng, R. Tang, I. McCaffery, K. Oliner, L. Chen, J. L. Gansert, E. Loh, D. Smethurst, J. Tabernero, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin. Cancer Res. 20, 4240-4250 (2014).
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 4240-4250
-
-
Van Cutsem, E.1
Eng, C.2
Nowara, E.3
Swieboda-Sadlej, A.4
Tebbutt, N.5
Mitchell, E.P.6
Davidenko, I.7
Stephenson, J.8
Elez, M.E.9
Prenen, H.10
Deng, H.11
Tang, R.12
McCaffery, I.13
Oliner, K.14
Chen, L.15
Gansert, J.L.16
Loh, E.17
Smethurst, D.18
Tabernero, J.19
-
41
-
-
69449084698
-
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
-
H. Piessevaux, M. Buyse, W. De Roock, H. Prenen, M. Schlichting, E. Van Cutsem, S. Tejpar, Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann. Oncol. 20, 1375-1382 (2009).
-
(2009)
Ann. Oncol.
, vol.20
, pp. 1375-1382
-
-
Piessevaux, H.1
Buyse, M.2
De Roock, W.3
Prenen, H.4
Schlichting, M.5
Van Cutsem, E.6
Tejpar, S.7
-
42
-
-
84891516390
-
Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab
-
H. Piessevaux, M. Buyse, M. Schlichting, E. Van Cutsem, C. Bokemeyer, S. Heeger, S. Tejpar, Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 31, 3764-3775 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 3764-3775
-
-
Piessevaux, H.1
Buyse, M.2
Schlichting, M.3
Van Cutsem, E.4
Bokemeyer, C.5
Heeger, S.6
Tejpar, S.7
-
43
-
-
79956022110
-
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations
-
F. Galimi, D. Torti, F. Sassi, C. Isella, D. Corà, S. Gastaldi, D. Ribero, A. Muratore, P. Massucco, D. Siatis, G. Paraluppi, F. Gonella, F. Maione, A. Pisacane, E.David, B. Torchio, M. Risio, M. Salizzoni, L. Capussotti, T. Perera, E. Medico, M. F. Di Renzo, P. M. Comoglio, L. Trusolino, A. Bertotti, Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations. Clin. Cancer Res. 17, 3146-3156 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 3146-3156
-
-
Galimi, F.1
Torti, D.2
Sassi, F.3
Isella, C.4
Corà, D.5
Gastaldi, S.6
Ribero, D.7
Muratore, A.8
Massucco, P.9
Siatis, D.10
Paraluppi, G.11
Gonella, F.12
Maione, F.13
Pisacane, A.14
David, E.15
Torchio, B.16
Risio, M.17
Salizzoni, M.18
Capussotti, L.19
Perera, T.20
Medico, E.21
Di Renzo, M.F.22
Comoglio, P.M.23
Trusolino, L.24
Bertotti, A.25
more..
-
44
-
-
77449088691
-
Only a subset of Met-activated pathways are required to sustain oncogene addiction
-
A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino, Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal. 2, ra80 (2009).
-
(2009)
Sci. Signal.
, vol.2
, pp. ra80
-
-
Bertotti, A.1
Burbridge, M.F.2
Gastaldi, S.3
Galimi, F.4
Torti, D.5
Medico, E.6
Giordano, S.7
Corso, S.8
Rolland-Valognes, G.9
Lockhart, B.P.10
Hickman, J.A.11
Comoglio, P.M.12
Trusolino, L.13
-
45
-
-
84860540538
-
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
-
G. Migliardi, F. Sassi, D. Torti, F. Galimi, E. R. Zanella, M. Buscarino, D. Ribero, A. Muratore, P. Massucco, A. Pisacane, M. Risio, L. Capussotti, S. Marsoni, F. Di Nicolantonio, A. Bardelli, P. M. Comoglio, L. Trusolino, A. Bertotti, Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin. Cancer Res. 18, 2515-2525 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 2515-2525
-
-
Migliardi, G.1
Sassi, F.2
Torti, D.3
Galimi, F.4
Zanella, E.R.5
Buscarino, M.6
Ribero, D.7
Muratore, A.8
Massucco, P.9
Pisacane, A.10
Risio, M.11
Capussotti, L.12
Marsoni, S.13
Di Nicolantonio, F.14
Bardelli, A.15
Comoglio, P.M.16
Trusolino, L.17
Bertotti, A.18
-
46
-
-
85027944392
-
LAS: A software platform to support oncological data management
-
E. Baralis, A. Bertotti, A. Fiori, A. Grand, LAS: A software platform to support oncological data management. J. Med. Syst. 36 (Suppl. 1), S81-S90 (2012).
-
(2012)
J. Med. Syst.
, vol.36
, pp. S81-S90
-
-
Baralis, E.1
Bertotti, A.2
Fiori, A.3
Grand, A.4
-
47
-
-
0025040604
-
Cytogenetics and DNA amplification in colorectal cancers
-
S. Brüderlein, K. van der Bosch, P. Schlag, M. Schwab, Cytogenetics and DNA amplification in colorectal cancers. Genes Chromosomes Cancer 2, 63-70 (1990).
-
(1990)
Genes Chromosomes Cancer
, vol.2
, pp. 63-70
-
-
Brüderlein, S.1
Van Der Bosch, K.2
Schlag, P.3
Schwab, M.4
|